People with ulcerative colitis, a form of IBD, who were taking the new drug Omvoh and achieved clinical remission after 1 ...
The updated indication for the JAK inhibitor allows use in patients with moderately to severely active ulcerative colitis and ...
The FDA has approved golimumab for the treatment of children with moderately to severely active ulcerative colitis who weigh ...
Once-daily oral obefazimod met the primary endpoint of clinical remission at 8 weeks in a highly refractory population of ...
Eli Lilly’s ulcerative colitis (UC) treatment, Omvoh (mirikizumab), has shown sustained positive outcomes in patients with ...
ABIVAX Société Anonyme's Obefazimod shows robust efficacy and differentiation in early Phase 3 trials. Click here to read why ...
Icotrokinra met the primary endpoint of clinical response at all three doses, with 36.5% of patients treated achieving ...
GlobalData on MSN
FDA approves AbbVie’s Rinvoq for inflammatory bowel disease
The US Food and Drug Administration (FDA) has approved AbbVie’s supplemental new drug application, updating the indication ...
1don MSN
Eli Lilly Omvoh Demonstrates Sustained Long-Term Benefits in Ulcerative Colitis Up to Four Years
Eli Lilly and Company (NYSE:LLY) is one of the best growth stocks to buy now. On October 7, Eli Lilly and Company announced ...
Johnson & Johnson's Simponi gains FDA approval for treating pediatric ulcerative colitis, expanding options for young patients with this chronic condition.
The rollout of a drug recommended by the National Institute of Health and Care Excellence is 'really exciting' news for UK ...
Crohn's disease and ulcerative colitis. Here's how to tell which one you have.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback